Drug details

Adstiladrin (nadofaragene firadenovec-vncg suspension, for intravesical use)

type of Biological Response Modifiers

Adstiladrin (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• weakness,
• shortness of breath, and
• blood in your urine,
• fast heart rate
• urinary urgency,
• urinary incontinency,
• urinary frequency,  
• pain or discomfort when urinating,
• abnormal lab results,

The following drugs are related to Adstiladrin, either as a replacement or used together:

• Bavencio (avelumab injection)
• Balversa (erdafitinib tablets)
• Padcev (enfortumab vedotin-ejfv for injection)
• Jelmyto (mitomycin for pyelocalyceal solution)
• Keytruda (pembrolizumab for injection)
• Opdivo (nivolumab injection)
• Pemazyre (pemigatinib tablets)
• Tepadina (thiotepa for injection)
• Valstar (valrubicin)